S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Bellerophon Therapeutics Stock Forecast, Price & News

-0.07 (-1.09 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $6.34
50-Day Range
MA: $7.41
52-Week Range
Now: $6.34
Volume81,200 shs
Average Volume77,153 shs
Market Capitalization$60.22 million
P/E RatioN/A
Dividend YieldN/A
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Bellerophon Therapeutics logo


Bellerophon Therapeutics EPS misses by $0.01
November 5, 2020 |  seekingalpha.com
Bellerophon Therapeutics Inc
October 16, 2020 |  bloomberg.com
Bellerophon to Present at Two September Investor Conferences
September 14, 2020 |  finance.yahoo.com
Insider Buys Bellerophon Therapeutics Shares
September 14, 2020 |  feeds.benzinga.com
Bellerophon Therapeutics EPS beats by $0.21
August 5, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:BLPH
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$0.78 per share


Net Income$-13,270,000.00


Market Cap$60.22 million
Next Earnings Date4/5/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.76 out of 5 stars

Medical Sector

184th out of 1,968 stocks

Pharmaceutical Preparations Industry

84th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
-0.07 (-1.09 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BLPH News and Ratings via Email

Sign-up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

Is Bellerophon Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Bellerophon Therapeutics stock.
View analyst ratings for Bellerophon Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Bellerophon Therapeutics?

Wall Street analysts have given Bellerophon Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bellerophon Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, April 5th 2021.
View our earnings forecast for Bellerophon Therapeutics

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) issued its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.83) by $0.01.
View Bellerophon Therapeutics' earnings history

How has Bellerophon Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Bellerophon Therapeutics' stock was trading at $6.29 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BLPH shares have increased by 0.8% and is now trading at $6.34.
View which stocks have been most impacted by COVID-19

When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work?

Bellerophon Therapeutics shares reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for BLPH?

4 Wall Street analysts have issued 12-month price objectives for Bellerophon Therapeutics' shares. Their forecasts range from $19.00 to $35.00. On average, they anticipate Bellerophon Therapeutics' stock price to reach $26.50 in the next year. This suggests a possible upside of 318.0% from the stock's current price.
View analysts' price targets for Bellerophon Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the following people:
  • Mr. Fabian Tenenbaum, CEO & Director (Age 47, Pay $814.29k)
  • Mr. Assaf Korner, CFO & Sec. (Age 43, Pay $423.08k)
  • Mr. Peter Fernandes, Chief Regulatory & Safety Officer (Age 66, Pay $468.64k)
  • Dr. Parag Suresh Shah, VP of Bus. Operations (Age 44)
  • Ms. Amy Edmonds, VP of Clinical Operations & Admin. (Age 49)
  • Dr. Edwin L. Parsley, Acting Chief Medical Officer (Age 60)

Who are some of Bellerophon Therapeutics' key competitors?

What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.31%), Renaissance Technologies LLC (2.26%), Wells Fargo & Company MN (2.13%), Northern Trust Corp (0.94%), GSA Capital Partners LLP (0.63%) and JPMorgan Chase & Co. (0.11%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock, Theodore T Wang and Wassim Fares.
View institutional ownership trends for Bellerophon Therapeutics

Which major investors are selling Bellerophon Therapeutics stock?

BLPH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Northern Trust Corp.
View insider buying and selling activity for Bellerophon Therapeutics
or view top insider-selling stocks.

Which major investors are buying Bellerophon Therapeutics stock?

BLPH stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, GSA Capital Partners LLP, BlackRock Inc., LPL Financial LLC, and JPMorgan Chase & Co.. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Fabian Tenenbaum, Jonathan M Peacock, Theodore T Wang, and Wassim Fares.
View insider buying and selling activity for Bellerophon Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $6.34.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics has a market capitalization of $60.22 million. The biotechnology company earns $-13,270,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis.

How many employees does Bellerophon Therapeutics have?

Bellerophon Therapeutics employs 18 workers across the globe.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is www.bellerophon.com.

Where are Bellerophon Therapeutics' headquarters?

Bellerophon Therapeutics is headquartered at 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected]

This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.